Prognosis and treatment of patients with acute alcoholic hepatitis

References

• Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360(26):2758-69
   PubMed Web of Science ®Google Scholar
• Lischner MW, Alexander JF, Galambos JT. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis 1971;16(6):481-94
   PubMedGoogle Scholar
• Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981;10(2):417-41
   PubMedGoogle Scholar
• Basra G, Basra S, Parupudi S. Symptoms and signs of acute alcoholic hepatitis. World J Hepatol 2011;3(5):118-20
   PubMedGoogle Scholar
• Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol 2002. 27(1):3-6
   Google Scholar
• Trabut JB, Plat A, Thepot V, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008;43(5):559-63
   PubMedGoogle Scholar
• Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25(1):108-11
   PubMed Web of Science ®Google Scholar
• O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010;51(1):307-28
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Lackner C, Stauber R, et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011;55(5):1103-11
   PubMedGoogle Scholar
• Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971;56(6):515-25
   PubMedGoogle Scholar
• Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2(1):33-42
   PubMedGoogle Scholar
• Deleuran T, Gronbaek H, Vilstrup H, Jepsen P. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther 2012;35(11):1336-42
   PubMedGoogle Scholar
• Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;38(6):584-95
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Uemura M, Kojima H, et al. Prognostic factors in severe alcoholic liver injury. Nara Liver Study Group. Alcohol Clin Exp Res 1999;23(4 Suppl):33S-8S
   PubMedGoogle Scholar
• Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl 1994;2:335-43
   PubMedGoogle Scholar
• Blitzer BL, Mutchnick MG, Joshi PH, et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977;22(6):477-84
   PubMedGoogle Scholar
• Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110(9):685-90
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53(3):397-417
   PubMed Web of Science ®Google Scholar
• Mutimer DJ, Burra P, Neuberger JM, et al. Managing severe alcoholic hepatitis complicated by renal failure. Q J Med 1993;86(10):649-56
   PubMedGoogle Scholar
• Elphick DA, Dube AK, McFarlane E, et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007;102(4):780-8
   PubMedGoogle Scholar
• Spahr L, Rubbia-Brandt L, Genevay M, et al. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis. BMC Gastroenterol 2011;11:115
   PubMedGoogle Scholar
• Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy – indications, adequacy, quality of specimens, and complications – a systematic review. J Hepatol 2007;47(2):284-94
   PubMed Web of Science ®Google Scholar
• Poynard T, Degott C, Munoz C, Lebrec D. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. Effect of acute alcoholic hepatitis on portal hypertension. Dig Dis Sci 1987;32(4):337-43
   PubMedGoogle Scholar
• Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 2007;25(7):841-8
   PubMedGoogle Scholar
• Palaniyappan N, Subramanian V, Ramappa V, et al. The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway? Int J Hepatol 2012;2012:624675
   PubMedGoogle Scholar
• Forrest EH, Gleeson D. Is a liver biopsy necessary in alcoholic hepatitis? J Hepatol 2012;56(6):1427-8. author reply 1428-1429
   PubMedGoogle Scholar
• Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75(2):193-9
   PubMed Web of Science ®Google Scholar
• Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41(2):353-8
   PubMed Web of Science ®Google Scholar
• Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2
   PubMedGoogle Scholar
• Soultati AS, Dourakis SP, Alexopoulou A, et al. Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J Gastroenterol 2006;12(25):4020-5
   PubMedGoogle Scholar
• Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005;42(5):700-6
   PubMedGoogle Scholar
• Papastergiou V, Tsochatzis EA, Pieri G, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: a cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther 2014;39(7):721-32
   PubMed Web of Science ®Google Scholar
• Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54(8):1174-9
   PubMed Web of Science ®Google Scholar
• Tripodi A, Caldwell SH, Hoffman M, et al. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007;26(2):141-8
   PubMed Web of Science ®Google Scholar
• Mayo Clinic. Available from: www.mayoclinic.org/meld/mayomodel6.html
   Google Scholar
• Lolekha PH, Sritong N. Comparison of techniques for minimizing interference of bilirubin on serum creatinine determined by the kinetic Jaffe reaction. J Clin Lab Anal 1994;8(6):391-9
   PubMedGoogle Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007;13(4):523-9
   PubMed Web of Science ®Google Scholar
• Arjal R, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis 2009;13(1):67-71
   PubMedGoogle Scholar
• Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl 2003;9(1):19-21
   PubMedGoogle Scholar
• Vaa BE, Asrani SK, Dunn W, et al. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011;86(1):37-42
   PubMedGoogle Scholar
• Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92(1):208-14
   PubMed Web of Science ®Google Scholar
• Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007;56(12):1743-6
   PubMedGoogle Scholar
• Dominguez M, Rincon D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103(11):2747-56
   PubMed Web of Science ®Google Scholar
• Forrest EH, Fisher NC, Singhal S, et al. Comparison of the Glasgow alcoholic hepatitis score and the ABIC score for the assessment of alcoholic hepatitis. Am J Gastroenterol 2010;105(3):701-2
   PubMedGoogle Scholar
• Lafferty H, Stanley AJ, Forrest EH. The management of alcoholic hepatitis: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2013;38(6):603-10
   PubMed Web of Science ®Google Scholar
• Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003;38(6):1363-9
   PubMed Web of Science ®Google Scholar
• Morris JM, Forrest EH. Bilirubin response to corticosteroids in severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005;17(7):759-62
   PubMedGoogle Scholar
• Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45(6):1348-54
   PubMedGoogle Scholar
• Lille Model. Available from: www.lillemodel.com/score.asp?score=lillept
   Google Scholar
• Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60(2):255-60
   PubMedGoogle Scholar
• Sandahl TD, Jepsen P, Ott P, Vilstrup H. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand J Gastroenterol 2011;46(9):1127-32
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005(1):CD001867
   PubMedGoogle Scholar
• Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2005;6(12):2103-15
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370(9603):1915-22
   PubMed Web of Science ®Google Scholar
• Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995;19(3):635-41
   PubMed Web of Science ®Google Scholar
• Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol 1985;1(2):141-51
   PubMedGoogle Scholar
• Soberon S, Pauley MP, Duplantier R, et al. Metabolic effects of enteral formula feeding in alcoholic hepatitis. Hepatology 1987;7(6):1204-9
   PubMedGoogle Scholar
• Cabre E. Nutrition in alcoholic steatohepatitis: more of the same or something new? Curr Opin Clin Nutr Metab Care 2008;11(5):626-31
   PubMedGoogle Scholar
• Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000;32(1):36-42
   PubMed Web of Science ®Google Scholar
• Alvarez MA, Cabre E, Lorenzo-Zuniga V, et al. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004;16(12):1375-80
   PubMedGoogle Scholar
• Shumaker JB, Resnick RH, Galambos JT, et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978;69(4):443-9
   PubMedGoogle Scholar
• Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74(3):311-21
   PubMedGoogle Scholar
• Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74(2 Pt 1):169-73
   PubMedGoogle Scholar
• Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326(8):507-12
   PubMed Web of Science ®Google Scholar
• Campra JL, Hamlin EM Jr, Kirshbaum RJ, et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973;79(5):625-31
   PubMedGoogle Scholar
• Porter HP, Simon FR, Pope CE 2nd, et al. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971;284(24):1350-5
   PubMedGoogle Scholar
• Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113(4):299-307
   PubMed Web of Science ®Google Scholar
• Daures JP, Peray P, Bories P, et al. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis]. Gastroenterol Clin Biol 1991;15(3):223-8
   PubMedGoogle Scholar
• Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995;37(1):113-18
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato-Biliary Group systematic review with meta-analysis and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27(12):1167-78
   PubMedGoogle Scholar
• Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36(4):480-7
   PubMed Web of Science ®Google Scholar
• Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998;275(4 Pt 1):G605-11
   PubMedGoogle Scholar
• Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343(20):1467-76
   PubMed Web of Science ®Google Scholar
• Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000;32(4):579-86
   PubMedGoogle Scholar
• Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001;35(5):582-9
   PubMedGoogle Scholar
• Wang F, Wang BY. Corticosteroids or non-corticosteroids: a fresh perspective on alcoholic hepatitis treatment. Hepatobiliary Pancreat Dis Int 2011;10(5):458-64
   PubMedGoogle Scholar
• Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007;46(3):831-40
   PubMed Web of Science ®Google Scholar
• Gustot T, Maillart E, Bocci M, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol 2014;60(2):267-74
   PubMedGoogle Scholar
• Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137(2):541-8
   PubMedGoogle Scholar
• Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39(5):1390-7
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-85
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155(3):1230-6
   PubMed Web of Science ®Google Scholar
• Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993;187(3-5):447-63
   PubMedGoogle Scholar
• McClain CJ, Barve S, Deaciuc I, et al. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19(2):205-19
   PubMedGoogle Scholar
• Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1637-48
   PubMed Web of Science ®Google Scholar
• De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009;15(13):1613-19
   PubMedGoogle Scholar
• Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009(4):CD007339
   PubMedGoogle Scholar
• Parker R, Armstrong MJ, Corbett C, et al. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;37(9):845-54
   PubMedGoogle Scholar
• Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010;138(5):1755-62
   PubMedGoogle Scholar
• Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 2009;15(25):3194-5
   PubMedGoogle Scholar
• Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012;57(6):1664-71
   PubMedGoogle Scholar
• Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013;310(10):1033-41
   PubMedGoogle Scholar
• Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48(3):465-70
   PubMedGoogle Scholar
• Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37(4):448-55
   PubMed Web of Science ®Google Scholar
• Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38(4):419-25
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52(8):1182-7
   PubMedGoogle Scholar
• Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009;50(3):584-91
   PubMedGoogle Scholar
• Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99(2):255-60
   PubMed Web of Science ®Google Scholar
• Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135(6):1953-60
   PubMedGoogle Scholar
• Hirano T, Kaplowitz N, Tsukamoto H, et al. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 1992;16(6):1423-7
   PubMedGoogle Scholar
• Kurose I, Higuchi H, Miura S, et al. Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology 1997;25(2):368-78
   PubMedGoogle Scholar
• Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137(3):856-64. 864.e851
   PubMed Web of Science ®Google Scholar
• Bass S, Zook N. Intravenous acetylcysteine for indications other than acetaminophen overdose. Am J Health Syst Pharm 2013;70(17):1496-501
   PubMedGoogle Scholar
• Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis – a randomised clinical trial. J Hepatol 2006;44(4):784-90
   PubMedGoogle Scholar
• Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007;47(2):277-83
   PubMedGoogle Scholar
• Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010;53(6):1117-22
   PubMedGoogle Scholar
• Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365(19):1781-9
   PubMedGoogle Scholar
• Beresford TP, Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse – but where are the data? Liver Transpl 2000;6(6):777-8
   PubMedGoogle Scholar
• Shawcross DL, O’Grady JG. The 6-month abstinence rule in liver transplantation. Lancet 2010;376(9737):216-17
   PubMedGoogle Scholar
• Brown RS Jr. Transplantation for alcoholic hepatitis – time to rethink the 6-month "rule". N Engl J Med 2011;365(19):1836-8
   PubMedGoogle Scholar
• Burroughs AK. Liver transplantation for severe alcoholic hepatitis saves lives. J Hepatol 2012;57(2):451-2
   PubMedGoogle Scholar
• Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012;61(1):150-9
   PubMedGoogle Scholar
• Immordino G, Gelli M, Ferrante R, et al. Alcohol abstinence and orthotopic liver transplantation in alcoholic liver cirrhosis. Transplant Proc 2009;41(4):1253-5
   PubMed Web of Science ®Google Scholar
• Singal AK, Bashar H, Anand BS, et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012;55(5):1398-405
   PubMed Web of Science ®Google Scholar
• Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365(19):1790-800
   PubMed Web of Science ®Google Scholar
• Tandon P, Goodman KJ, Ma MM, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009;104(7):1700-6
   PubMed Web of Science ®Google Scholar
• Kulkarni K, Tran T, Medrano M, et al. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004;38(5):453-9
   PubMed Web of Science ®Google Scholar
• Kryger P, Schlichting P, Dietrichson O, Juhl E. The accuracy of the clinical diagnosis in acute hepatitis and alcoholic liver disease. Clinical versus morphological diagnosis. Scand J Gastroenterol 1983;18(5):691-6
   PubMed Web of Science ®Google Scholar
• Tilg H, Kaser A. Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress? Gut 2005;54(8):1057-9
   PubMedGoogle Scholar
• Forrest E, Mellor J, Stanton L, et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials 2013;14:262
   PubMedGoogle Scholar